Drug Profile
Golimumab biosimilar - Polpharma Biologics
Alternative Names: BOW 100Latest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator Bioceros
- Developer EPIRUS Biopharmaceuticals
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antiasthmatics; Antihyperglycaemics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies
- Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ankylosing spondylitis; Autoimmune disorders; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 13 Jul 2020 Polpharma Biologics acquired Bioceros and changed name to Polpharma Biologics
- 28 Dec 2019 No recent reports of development identified for research development in Ankylosing-spondylitis in USA
- 28 Dec 2019 No recent reports of development identified for research development in Autoimmune-disorders in USA